{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:40:27Z","timestamp":1761871227575,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Xinqiao Hospital of Army Military Medical University","award":["2016YLC03"],"award-info":[{"award-number":["2016YLC03"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.clml.2019.03.012","type":"journal-article","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T23:34:46Z","timestamp":1553556886000},"page":"e349-e358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Study on the Prognostic Value of Aberrant Antigen in Patients With Acute B Lymphocytic Leukemia"],"prefix":"10.1016","volume":"19","author":[{"given":"Jun","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Ying","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PeiYang","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian-Gui","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.03.012_bib1","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","article-title":"Modern therapy of acute lymphoblastic leukemia","volume":"29","author":"Bassan","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.012_bib2","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia; an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.012_bib3","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/sj.leu.2404824","article-title":"Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial","volume":"21","author":"Tavernier","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.03.012_bib4","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(12)70580-6","article-title":"Relapsed childhood acute lymphoblastic leukaemia","volume":"14","author":"Bhojwani","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2019.03.012_bib5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/asheducation.V2012.1.129.3800156","article-title":"Where do we stand in the treatment of relapsed acute lymphoblastic leukemia?","volume":"24","author":"Raetz","year":"2012","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2019.03.012_bib6","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1182\/blood-2012-08-234492","article-title":"The myth of the second remission of acute leukemia in the adult","volume":"121","author":"Forman","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.012_bib7","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.3109\/10428194.2013.856428","article-title":"Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia","volume":"55","author":"Dinner","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2019.03.012_bib8","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1182\/blood-2014-09-551937","article-title":"How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"126","author":"Frey","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.012_bib9","first-page":"837","article-title":"China's diagnosis and treatment of adult acute lymphoblastic leukemia guide","volume":"5","year":"2016","journal-title":"Chin J Hematol"},{"key":"10.1016\/j.clml.2019.03.012_bib10","first-page":"641","article-title":"Children with acute lymphoblastic leukemia treatment advice (fourth amendment) [J]","volume":"52","year":"2014","journal-title":"Chin J Pediatr"},{"key":"10.1016\/j.clml.2019.03.012_bib11","first-page":"732","article-title":"Improvement strategy of the efficacy after allogeneic hematopoietic stem cell transplantation for recurrent leukemia","volume":"38","author":"Sun","year":"2017","journal-title":"Chin J Hematol"},{"key":"10.1016\/j.clml.2019.03.012_bib12","doi-asserted-by":"crossref","unstructured":"NCCN Guidelines Insights: Acute Lymphoblastic Leukemia (Version 1.2017). 2017, Available at: https:\/\/doi.org\/10.6004\/jnccn.2017.0147. Accessed September 10, 2017.","DOI":"10.6004\/jnccn.2017.0147"},{"key":"10.1016\/j.clml.2019.03.012_bib13","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3324\/haematol.2009.014274","article-title":"Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group","volume":"95","author":"Oriol","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.03.012_bib14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"Biomark Res"},{"key":"10.1016\/j.clml.2019.03.012_bib15","first-page":"306","article-title":"Donor-derived CAR-T cells serve as a reduced-intensity conditioning regimen for haploidentical stem cell transplantation in treatment of relapsed\/refractory acute lymphoblastic leukemia: case report and review of the literature","volume":"41","author":"Zhang","year":"2018","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.clml.2019.03.012_bib16","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.012_bib17","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clml.2019.03.012_bib18","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.012_bib19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-017-0405-3","article-title":"Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies","volume":"10","author":"Liu","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2019.03.012_bib20","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2217\/imt-2017-0072","article-title":"CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"9","author":"Liu","year":"2017","journal-title":"Immunotherapy"},{"key":"10.1016\/j.clml.2019.03.012_bib21","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/pbc.20063","article-title":"CD19 negative precursor B acute lymphoblastic leukemia presenting with hypercalcemia","volume":"43","author":"Sultan","year":"2004","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2019.03.012_bib22","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clml.2019.03.012_bib23","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T\u00a0cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells","volume":"6","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.clml.2019.03.012_bib24","first-page":"305","article-title":"Impact of aberrant antigens in the outcome of patients with acute leukemia at a referral institution in Mexico City","volume":"68","author":"Rodr\u00edguez-Rodr\u00edguez","year":"2016","journal-title":"Rev Inves Clin"},{"key":"10.1016\/j.clml.2019.03.012_bib25","doi-asserted-by":"crossref","first-page":"221","DOI":"10.7314\/APJCP.2014.15.1.221","article-title":"Clinical significance of co-expression of aberrant antigens in acute leukemia: a retrospective cohort study in Makah Al Mukaramah, Saudi Arabia","volume":"15","author":"Abdulateef","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2019.03.012_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12288-014-0485-y","article-title":"CD5 positive B lymphoblastic leukemia: report of a case with review of literature","volume":"32","author":"Sreedharanunni","year":"2016","journal-title":"India J Hematol Blood Transfus"},{"key":"10.1016\/j.clml.2019.03.012_bib27","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3324\/haematol.2018.205252","article-title":"CD123 expression patterns and selective targeting with a CD123-specific antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia","volume":"104","author":"Angelova","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.03.012_bib28","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1080\/104281090310001646031","article-title":"Immunophenotypic features of acute myeloid leukemias overexpressing the interleukin 3 receptor alpha chain","volume":"45","author":"Riccioni","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2019.03.012_bib29","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clml.2019.03.012_bib30","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/leu.2017.145","article-title":"High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients","volume":"31","author":"Pan","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.03.012_bib31","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen\u00a0receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.012_bib32","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/bjh.14923","article-title":"Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation","volume":"179","author":"Chen","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.03.012_bib33","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.012_bib34","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.012_bib35","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1182\/blood-2004-03-0901","article-title":"Characterization of acute lymphoblastic leukemia progenitor cells","volume":"104","author":"Cox","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.012_bib36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1053\/j.seminhematol.2008.09.010","article-title":"Leukemia stem cells and human acute lymphoblastic leukemia","volume":"46","author":"Bernt","year":"2009","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2019.03.012_bib37","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2002-03-0852","article-title":"Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis","volume":"100","author":"Testa","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.012_bib38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.stem.2009.04.018","article-title":"Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells","volume":"5","author":"Jin","year":"2009","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.clml.2019.03.012_bib39","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1007\/s13277-015-3272-y","article-title":"Interleukin-3 receptor \u03b1 chain (CD123) is preferentially expressed in immature T-ALL and may not associate with outcomes of chemotherapy","volume":"37","author":"Du","year":"2016","journal-title":"Tumour Biol"},{"key":"10.1016\/j.clml.2019.03.012_bib40","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood.V122.21.143.143","article-title":"Anti-CD123 chimeric antigen receptor T cells (CART-123) provide a novel myeloablative conditioning regimen that eradicates human acute myeloid leukemia in preclinical models","volume":"122","author":"Gill","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.012_bib41","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","article-title":"T\u00a0cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia","volume":"122","author":"Mardiros","year":"2013","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019301211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019301211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:32:04Z","timestamp":1761870724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019301211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S2152265019301211"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.03.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Study on the Prognostic Value of Aberrant Antigen in Patients With Acute B Lymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}